Grand Pharmaceutical Advances Phase III Trial of Innovative Cancer Treatment in China

An update from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.

Grand Pharmaceutical Group Limited has announced the completion of the first patient enrolment and dosing in China for its international multi-center Phase III clinical trial of ITM-11, an innovative RDC product. This trial is part of a strategic collaboration with ITM Isotope Technologies Munich SE, granting the company exclusive rights in Greater China. The trial aims to evaluate ITM-11’s efficacy and safety for treating aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company also plans a bridging trial to expand ITM-11’s use in China, supported by successful overseas trial data. ITM-11, which has received orphan drug designation in the US and EU, could significantly impact the treatment landscape for GEP-NETs, offering a new integrated diagnosis and treatment option.

More about Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on the development, production, and commercialization of innovative radionuclide-drug conjugate (RDC) products. The company has a strategic market focus in Greater China, including Mainland China, Hong Kong, Macau, and Taiwan.

YTD Price Performance: 27.29%

Average Trading Volume: 6,000,343

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$21.69B

For detailed information about 0512 stock, go to TipRanks’ Stock Analysis page.